Company intelligence / Profile preview

Selah Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Developing novel ketone-based therapies for chronic diseases of aging with a primary focus on heart disease. No specific clinical results mentioned in the search results.

Therapeutic areas: OtherCardiovascular
Modalities: Ketone-based therapies
Industry: Biotech

Drug pipeline

2 assets

SER-252

Pre-clinical

Indications: Parkinson's disease

1 more asset in the full pipeline.

Request access →

Partnerships

JuvenescenceBuck Institute for Research on Aging

Beyond the preview

Go deeper on Selah Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selah Therapeutics.

Explore the full profile